Data Presented at the 2019 Genitourinary Cancers Symposium
Reinforces Benefits of Short Course of Treatment Using Stereotactic
Body Radiation Therapy for Low- or Intermediate-Risk
Prostate Cancer
SUNNYVALE, California,
Feb. 22, 2019 /PRNewswire/
-- Accuray Incorporated (NASDAQ: ARAY) announced today that
data from an international, randomized, 38-center trial (PACE -
Prostate Advances in Comparative Evidence) show that treatment with
stereotactic body radiation therapy (SBRT) results in a similar
safety profile to conventional radiation in men with low- or
intermediate-risk prostate cancer. The study was presented during
an oral session at the recent American Society of Clinical Oncology
Genitourinary Cancers Symposium (ASCO GU) in San Francisco, California.
SBRT involves the delivery of very high doses of
externally-administered radiation over a small number of treatment
sessions, offering convenience for patients, compared to
conventional radiation therapy which requires a substantially
longer course of treatment. In the PACE trial, SBRT was delivered
in five sessions while conventional radiation therapy was delivered
in 20 or 39 sessions. The Phase 3 trial found that despite the high
dose delivered to the prostate, use of SBRT and conventional
radiation therapy result in comparable rates of acute
gastrointestinal and genitourinary toxicity.
"There has been considerable discussion and analysis of the
risks versus the benefits of different radiation treatment
techniques, especially in patients with low- or intermediate-risk
prostate cancer, in large part because the side effects of
treatment can impact quality of life. One of the clinical trial
goals was to determine whether SBRT or a more conventionally
fractionated radiotherapy schedule would provide a safer treatment
choice," said Nicholas van As, M.D., Medical Director and
Consultant Clinical Oncologist of The Royal Marsden NHS Foundation
Trust and Reader at the ICR, London,
United Kingdom and lead investigator of the trial. "These
early trial results are very promising and help us better
understand the effect of different radiation therapy techniques on
the treatment of prostate cancer. We look forward to analyzing
additional trial data as it becomes available."
The prostate gland can move unpredictably throughout the course
of treatment because of normal patient bodily functions. This makes
it vitally important to be able to track, detect and correct for
all types of motion. The CyberKnife® System, designed to
deliver SBRT, is the only radiotherapy device that can track and
automatically correct for prostate motion and maintain
sub-millimeter accuracy throughout treatment delivery, thereby
enhancing clinicians' ability to treat effectively while preserving
healthy tissue.
"The results of this randomized controlled trial add to the
large body of evidence supporting the use of SBRT as a treatment
option for low- and intermediate-risk prostate cancer. The data are
important because they have the potential to impact clinicians'
approach to the treatment of this disease," said Fabienne
Hirigoyenberry-Lanson, Ph.D., Vice President Global Medical and
Scientific Affairs at Accuray. "Our CyberKnife System provides a
valuable option for delivering prostate SBRT. Data reinforce that
treatment with the system results in minimal side effects and
impact on quality of life during and after treatment."
About the PACE-B Trial
PACE-B, an international phase 3 randomized controlled trial
comparing stereotactic body radiotherapy to conventionally
fractionated or moderately hypofractionated external beam
radiotherapy (CFMHRT) for localized prostate cancer, represents one
arm of a two-part trial. Further data on this arm, as well as the
second arm comparing hypofractionated SBRT to prostatectomy, will
be shared when available. Out of the 874 patients enrolled by 38
institutions, 845 patients were analyzed; 431 receiving SBRT and
414 CFMHRT. Men who were unsuitable for surgery or preferred
treatment with external beam radiation therapy were eligible to
participate. The trial evaluated the treatment regimens across
multiple effectiveness and safety metrics; toxicity measures were
presented at ASCO GU.
About Accuray
Accuray Incorporated (Nasdaq: ARAY) is a radiation oncology company
that develops, manufactures and sells precise, innovative treatment
solutions that set the standard of care with the aim of helping
patients live longer, better lives. The company's leading-edge
technologies deliver the full range of radiation therapy and
radiosurgery treatments. For more information, please visit
www.accuray.com or follow us on Facebook, LinkedIn, Twitter and
YouTube.
Safe Harbor Statement
Statements made in this press release that are not statements of
historical fact are forward-looking statements and are subject to
the "safe harbor" provisions of the Private Securities Litigation
Reform Act of 1995. Forward-looking statements in this press
release relate, but are not limited, to clinical applications,
clinical results, patient experiences and outcomes, the impact of
data on clinicians' decision-making, and Accuray's leadership
position in radiation oncology innovation and technologies. These
forward-looking statements involve risks and uncertainties. If any
of these risks or uncertainties materialize, or if any of the
company's assumptions prove incorrect, actual results could differ
materially from the results expressed or implied by these
forward-looking statements. These risks and uncertainties include,
but are not limited to, the company's ability to achieve widespread
market acceptance of its products, including new product offerings,
the company's ability to develop new products or enhance existing
products to meet customers' needs, delays in the development or
release of new offerings and such other risks identified under the
heading "Risk Factors" in the company's annual report on Form 10-K,
filed with the Securities and Exchange Commission (the "SEC") on
August 24, 2018, the company's
quarterly report on Form 10-Q, filed with the SEC on February 8, 2019, and as updated periodically
with the company's other filings with the SEC.
Forward-looking statements speak only as of the date the
statements are made and are based on information available to the
company at the time those statements are made and/or management's
good faith belief as of that time with respect to future
events. The company assumes no obligation to update
forward-looking statements to reflect actual performance or
results, changes in assumptions or changes in other factors
affecting forward-looking information, except to the extent
required by applicable securities laws. Accordingly, investors
should not put undue reliance on any forward-looking
statements.
Media
Contacts:
|
|
Beth
Kaplan
|
Jayme
Maniatis
|
Public Relations
Director, Accuray
|
MSLGROUP
|
+1 (408)
789-4426
|
+1 (781)
684-6610
|
bkaplan@accuray.com
|
accuray@mslgroup.com
|